BridgeBio Pharma, Inc. 4

Director Jennifer E. Cook exercised 148,589 BridgeBio Pharma stock options and sold 148,589 common shares (mainly at $84–$90) under a Rule 10b5-1 plan, ending with 8,383 shares owned.

On July 9, 2026, BridgeBio Pharma, Inc. director Jennifer E. Cook exercised three tranches of stock options for an aggregate 148,589 shares of common stock at exercise prices of $8.45, $29.00, and $16.75 per share, then sold 148,589 shares into the market pursuant to a pre-established Rule 10b5-1 trading plan. Specifically, she exercised 19,000 options at $8.45, 112,422 options at $29.00, and 17,167 options at $16.75, acquiring the same number of common shares in each case, and subsequently sold 36,167 shares at $84.00 and 112,422 shares at $90.00, effectively monetizing a substantial portion of her option-derived holdings. Following these transactions, she reported direct ownership of 8,383 shares of BridgeBio common stock, indicating that the activity primarily reflects option exercises paired with sizable liquidity-driven sales rather than an increase in net equity exposure.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

4

Source Type

fda

Accession

0001470831-26-000708

Alert Tier

7